KAICO Ltd.
Exhibitor
KAICO Ltd. is a biotechnology company originating from Japan, pioneering a proprietary silkworm–baculovirus protein expression platform that enables efficient production of complex recombinant proteins which are difficult to manufacture using conventional systems.
At the World Vaccine Congress Europe 2026, KAICO will showcase its core technology alongside its human norovirus vaccine candidate, developed using silkworm pupae as living bioreactors. This unique approach allows high-yield expression of structurally complex antigens, including virus-like particles (VLPs), with excellent scalability and cost efficiency.
KAICO’s norovirus vaccine candidate is designed to address a significant unmet medical need in global infectious disease control and is scheduled to enter Phase I clinical trials in mid-2026. By combining a proven insect-based expression system with rigorous vaccine development expertise, KAICO aims to expand the possibilities of next-generation vaccines for both human and animal health.
We welcome discussions with pharmaceutical companies, vaccine developers, and research partners interested in innovative antigen production, vaccine co-development, and strategic collaboration.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events